[Asia Economy Reporter Chunhee Lee] Hyundai Pharm announced on the 12th that it has received approval from the Ministry of Food and Drug Safety for the marketing authorization of the Alzheimer's-type dementia treatment drug 'Hypegil-san 5mg, 10mg (Donepezil Hydrochloride Hydrate)'.
'Hypegil-san 5mg, 10mg' is a dementia treatment drug containing donepezil as the active ingredient, which is widely used for patients with Alzheimer's-type dementia. Hyundai Pharm, which previously held and sold Hypegil tablets 5mg, 10mg, and 23mg, will now launch a new formulation in the form of a powder through this approval.
A Hyundai Pharm official stated, "Due to the nature of donepezil, it is mainly taken by elderly patients who often have difficulty swallowing tablets, so it is common to crush tablets and prepare them as powders. To address the difficulties in the dispensing process and improve patients' medication adherence, we have developed the powder formulation for the first time."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
